Summary
We have investigated the role of metronidazole (MND) combined with 5-fluorouracil (5-FU) in the treatment of metastatic colorectal cancer. MND (750 mg/m2) was administered i.v. 1 h before 5-FU (600 mg/m2) i.v., daily for 5 consecutive days. Treatment was repeated every 4 weeks until disease progression or prohibitive toxicity occurred. Of the 27 patients entered in the study, 4 (15%) had an objective complete or partial response lasting an average of 7 months. 5-FU toxicity was greatly enhanced by the administration of MND, however, 74% of patients having granulocytopenia (<1500/μl). We investigated the possible mechanisms underlying this enhanced 5-FU toxicity by examining whether MND modified 5-FU pharmacokinetics or whether the two drugs had a synergistic effect in vitro against the HCT-8 colon cancer cell line. While the in vitro studies failed to reveal any synergism between 5-FU and MND, pharmacokinetic evaluation revealed that 5-FU clearance was significantly reduced (26.9%, P<0.001) by prior MND administration. MND reduces 5-FU's therapeutic index in the treatment of colorectal cancer by impairing its clearance, which leads to increased toxicity without enhanced therapeutic efficacy.
Similar content being viewed by others
References
Au JL, Walker JS, Rustum Y (1983) Studies of 5-fluorouracil and 5-deoxy-5-fluorouridine in rats. J Pharmacol Exp Ther 227: 174
Cohen JL, Brown RE (1978) High performance liquid chromatography analysis of 5-FU in plasma. J Chromatogr 151: 237
Hill PR, Stanley JA (1975) The response of hypoxic β16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res 35: 1147
Kelly JP, Hannan TW, Gill GR (1979) The cytocidal action of metronidazole in combination with other entineoplastic agents. Cancer Treat Rev 6 [suppl]: 53
McDermott BJ, Van Den Berg HW, Martin WMC, Murphy RF (1983) Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans. Br J Cancer 48: 705
Moertel CG (1975) Clinical management of advanced gastrointestinal cancer 36: 675
Moertel CG, Schutt AJ, Reitmer RJ, Hahn RG (1972) A comparison of 5-FU administration by slow infusion and rapid injection. Cancer Res 32: 2717
Petrelli NJ, Mittelman A (1984) An analysis of chemotherapy for colorectal carcinoma. J Surg Oncol 25: 201
Roizin-Towle L, Hall EJ (1978) Studies with bleomycin and misonidazole on areated and hypoxic cells. Br J Cancer 37: 254
Siemann DW (1982) Potentiation of chemotherapy by hypoxic cell radiation sensitizer — A review. Int J Radiat Oncol Biol Phys 8: 1029
Silverberg E (1985) Cancer statistics. CA 35: 19
Smith E, Lumley CE, Stratford IJ, Adams GE (1982) Chemosensitization in vitro: Potentiation of melphalum toxicity by misonidazole, metronidazole and nitrofurazone. Int J Radiat Oncol Biol Phys 8: 615
Spooner D, Bugden RD, Reckham MJ, Wist EA (1982) The combination of 5-fluorouracil with misonidazole in patients with advanced colorectal cancer. Int J Radiat Oncol Biol Phys 8: 387
Stephens TC, Courtnay VD, Mills J, Peacock JH, Rose CM, Spooner D (1981) Enhanced cell killing in Lewis lung carcinoma and a human pancreatic carcinoma and a human pancreatic carcinoma xenograft by the combination of cytotoxic drugs and misonidazole. Br J Cancer 43: 451
Stratford IJ, Adams GE, Horsman MR, Kandaiya S, Rajartnam S, Smith E, Williamson C (1980) The interaction of misonidazole with radiation, chemotherapeutic agents or heat. Cancer Clin Trials 3: 231
Sutherland RM (1974) Selective chemotherapy of non-cycling cells in an in vitro tumor model. Cancer Res 34: 3501
Tannock IF (1980) In vivo interaction of anti-cancer drugs with misonidazole a metronidazole: methotrexate, 5-fluorouracil and adriamycin. Br J Cancer 42: 861
Tompkins PJ, Watrach A, Schmale J, Schultz R, Harris J (1974) Cultural and antigenic properties of newly established cell strains derived from adenocarcinoma of the human colon and rectum. J Natl Cancer Inst 52: 1101
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bardakji, Z., Jolivet, J., Langelier, Y. et al. 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Cancer Chemother. Pharmacol. 18, 140–144 (1986). https://doi.org/10.1007/BF00262284
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262284